Skip to main content

Table 7 Nintedanib-placebo median treatment difference for absolute change from baseline to 52 weeks on each PRO measure, by stratification subgroup (analysis 3)

From: Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials